News

Agrospheres Completes Expansion of $25 Million Series B Round

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection, today announced the closing of its Series B funding round with a strategic investment from FMC Corporation (NYSE: FMC), a global leader in agriculture sciences. This investment brings the total funding in AgroSpheres’ Series B round to $25 million, demonstrating the strong confidence in the company’s innovative solutions. FMC Ventures joins Lewis and Clark AgriFood, Ospraie Ag Science, BIDRA Ventures, and Cavallo Ventures to close out the round.

AgroSpheres has developed cutting-edge technology that enables precise delivery of active ingredients such as small molecules, peptides, and nucleic acids in crop protection products. This technology has the potential to revolutionize the agriculture industry by improving the efficiency, efficacy, and sustainability of crop protection practices.

“We are excited to invest and partner with AgroSpheres, sharing a common vision for advancing agriculture,” said Mark Brooks, managing director, FMC Ventures. “Their innovative technology has the potential to be a game changer in crop protection. With broad IP protection, manufacturing capabilities, and a strong industry network, AgroSpheres stands out in AgTech. We believe this investment will drive innovation and accelerate the development of sustainable solutions for farmers globally.”

AgroSpheres’ Co-Founder and CEO, Payam Pourtaheri, also commented on the investment, saying, “We are honored to welcome FMC Corporation as a strategic investor in AgroSpheres. Their extensive expertise in agricultural sciences and global reach make them an ideal partner for us. This investment will further empower us to continue our mission of providing more effective and sustainable solutions for the agricultural industry. Together with FMC, we will strive to make a significant impact on global agriculture.”

AgroSpheres has gained recognition for its innovative approach to precision delivery of crop protection products, reducing environmental impact, and enhancing overall crop health. This latest investment will support the company in its mission to bring this technology to more markets, helping farmers worldwide address the challenges of feeding a growing global population while minimizing the environmental footprint.

Recent News

10/13/2025

InBio Secures $3.5 Million NIH Grant to Advance Allergy Research

InBio, a global leader in allergy research, was recently awarded a $3.5 million R01 grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This funding supports a groundbreaking initiative to develop innovative immunotherapeutic tools targeting allergens from house dust mites, cats, and dogs—major contributors to

10/09/2025

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

AstraZeneca announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at

10/09/2025

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the successful completion of the analytical validation of a cheek swab collection method for testing patients for both clinical trial usage as well as future commercial application. This major step marks a